COMPA Bulletin

For Week of April 8, 2001

 

 

Welcome

Welcome to the first issue of the new COMPA Bulletin, the purpose of which is to ensure that New York State providers of opioid treatment services have effective mechanisms for the dissemination of information and encouragement of dialogue.  It is our intention to  compile and distributed this Bulletin to all organizational and individual members of COMPA on a regular basis.  In the future, expect to see important communications from CSAT, OASAS, AMTA, ASAP, manufacturers and others; synopsis of new research, demonstration projects, accreditation experiences, professional journals, and books; announcements and reminders about upcoming meetings, training sessions, conferences, and events of interest to the field;  listings of resources and funding  opportunities;  committee reports;  surveys;  job opportunities; and professional and personal member announcements.   This newsletter will be mailed for the immediate future but it is our desire to provide timely information which can be easily disseminated.  As such, we are asking that COMPA members submit their email addresses to peter2820@aol.com as soon as possible.

 

Board of Directors

After revision of the COMPA’s by-laws and a vote to elect a new Board of Directors, the following individuals have been selected to serve terms of between 1 and 3 years: Herbert Barish, First Vice President of Lower Eastside Service Center, New York; Willard Campbell, Clinic Administrator from Suffolk County Division of Alcohol and Substance Abuse Services; Peter Coleman, Senior Director of Substance Abuse at the NYC Health and Hospitals Corporation; Eugenia Curet, Administrator at NY Presbyterian Cornell Medical Center MTP in Manhattan; Robert Krauss, Director of the Long Beach Hospital MMTP; Ira Marion, Executive Director of the Division of Substance Abuse at AECOM-Montefiore in the Bronx; Johanne Morne, Program Director at the Whitney Young MMTP in Albany; Robert Sage, Senior Vice President of A.R.T.C. in  Brooklyn; Sheila Tierney, Manager of Chemical Dependency at Crouse Hospital in Syracuse; Ira Wolfe, Director of the Unity Center at St. Like’s Hospital, Newburgh; and Richard Woytek, Director of the Long Island Jewish MMTP.   At the first meeting of the Board in January, Peter Coleman was selected to serve as President, Ira Marion was selected to serve as Vice President, Johanne Morne was selected as Secretary, and Richard Woytek was selected to continue as Treasurer.

 

Accreditation Update

The effective date of the Final Rule, which will replace the current FDA inspection-focused methadone regulations with a certification project administered by Center for Substance Abuse Treatment (CSAT), has been moved to May 18, 2001.   CSAT will shortly begin distributing to clinics prepared materials which provide a copy of the Final Rule, a Press Release which announces the issuance of the Final Rule, a Fact Sheet which provides a background and summarizes the intent of the Final Rule, an Info Sheet announcing CSAT sponsored Technical Assistance Workshops, and an Application for Certification to Use Opioid Drugs in a Treatment Program.  Important dates to keep in mind include May 18th when the rules become effective, the week of May 21 when CSAT will provide a day-long Technical Assistance Workshop in New York City, and August 17th, which is the deadline for submitting an Application for Certification. 

 

All programs in operation on May 18, 2001 will be considered by CSAT to be in transitional status.   Failure to submit an Application for Certification by August 17, 2001 will technically result in program being out of business.   After submitting the application, programs will then have two years to become accredited.  Programs will also be able to request a one year extension.  All exemptions currently in place will carry over.

 

CSAT states that a contract will be awarded to provide Technical Assistance to the programs during the transition period.   CSAT further stated that no money has been targeted specifically to assist methadone treatment programs with meeting accreditation standards, although there has been an increase in the state block grant funds, and providers could that some of this increase be allocated to methadone programs.  

                       

Methadone Product Availability

Uncertainty continues regarding the availability of Methadone Hydochloride after Ganes experienced problems with the manufacturing of the base product and was forced to shut down their manufacturing process.    UDL and Ganes officials state that they plan on reentering the market during May 2001, which currently leaves only Mallincrodt as the only stable source as  Roxanne is partially dependent on Ganes for  its base product.  Mallincrodt has pledged to maintain adequate supplies for clinics and inpatient units, but programs are advised to consider increasing their supplies on hand at least for the immediate future.  When all of this ends, price increases are also likely.

 

AMTA Conference

This year’s AMTA Conference will be held at the Regal Riverfront Hotel in St. Louis from October 7 – 10.  The deadline for Early Registration ends on April 15, after which standard registration fees apply.  In addition to the usual conference activities, both NIDA and CSAT are sponsoring numerous Pre-Conference Sessions which will begin on Saturday, October 6.  For Conference information contact Christine Rossiter or Michelle Thompson at Tally Management (856-423-7222 ex. 350)

 

Methadone & Criminal Justice Symposium

OASAS, the Department of Parole, and the Department of Probation are sponsoring a symposium on Wednesday, April 25, 2001, from 9:00 am to 3:30 pm at Albert Einstein College of Medicine.  The symposium will present a broad range of issues that impact upon methadone patients who may also be involved in the criminal justice system.  The Conference will also address concerns around methadone as a viable option for the courts, and attempt to bridge the gap in understanding that exists between the two systems.  Space is limited and reservations must be received by April 18th.  For more information or to register please contact Larry Samuels at 646-728-4580.

 

NYC Human Resources Administration

In an ironic twist, as the Federal Government moves ahead with providing regulatory relief from the burden of cumbersome rules which dictated medical treatment and limited access to methadone treatment, along comes the NYC Human Resources Administration to fill the void.  New York City programs recently received a letter from HRA asking them to sign a Letter of Agreement if they wish to remain on HRA’s approved provider list.  Among other things, this Letter of Agreement commits programs to adhering to the HRA Clinical Practice Guidelines, requires on-going detailed reporting, requires programs to obtain consent and then notify HRA when public assistance recipients apply for treatment, requires participation in the STARS Reporting System, and coordinate services and care with programs under HRA auspices.

 

General issues that have been identified by COMPA providers include:

(1)   Confidentiality – concern that the fear of having to disclose to HRA will discourage people in need who are receiving public assistance from seeking treatment; informed consent requires patient knowledge of the benefits and risks of disclosure to HRA, a document that has been requested but not provided; and questions arise about the ultimate need and purpose of HRA for such detailed information

(2)   Appropriate computer hardware, software, cabling and internet access is lacking in many programs. In addition, hospitals often have firewall and security issues that must be resolved in order to utilize STARS efficiently;

(3)   HRA reporting requirements have significantly increased, from approximately one hour per month per program in 1998 to anywhere from 1 – 4 hours per client per month now. OASAS has taken issue with the resultant decrease in counselor time available to provide direct services to patients.

(4)   Questions regarding HRA’s statutory authority to issue practice guidelines, as well as the concept of “mandating” guidelines and enforcing adherence which may restrict the program’s right to determine appropriate clinical treatment and measure progress towards individualized goals established by treatment plans.

(5)   Toxicology - most methadone treatment programs do not perform toxicology testing for all 7 substances as required by HRA nor test weekly beyond 90 days if the patient is stable, and to do so will incur additional costs;   Concern has been expressed that review of toxicology and attendance data outside of context of treatment may not reflect the actual progress a client has made. 

 

COMPA supports the mandates of the Welfare Reform Law which requires work in exchange for public assistance, and is appreciative of the task facing HRA in have individuals receiving public assistance move to self-sufficiency, participate in WEP activities, and move where possible from welfare to work.  COMPA recognizes as well that research has shown a positive relationship between work and recovery. COMPA remains concerned, however, about HRA’s approach in dealing with the treatment system as well as the lack of acknowledgement that for some individuals addiction is a life long disease which is severely debilitating. 

 

COMPA recommends that programs desiring to continue serving public assistance recipients known to HRA need to respond, either by signing this agreement or formally requesting an extension in order to have sufficient time to consider the various issues.  COMPA also recommends that programs not sign this agreement without considering the various issues involved, completing an assessment of program needs and impacts, and undertaking a legal review of the terms of the Letter of Agreement.  Towards this end, we understand that some of our members, after review by their attorneys, are planning to sign an amended Letter of Agreement, which addresses the language problems in the existing document. 

 

COMPA’s Executive Director Retires

Martin Livenstein, COMPA’s  Executive Director for 13 years, retired on March 2 and a retirement reception was held in his honor at the Griffis Faculty Club at New York – Presbyterian Hospital.  His humor, dedication and hard work over the years has been much appreciated by all and he will be sorely missed.  We wish him well. 

 

While the new Executive Director is being recruited, the Board has engaged Michael McAllister on a per diem basis to fill in and help out.  Please bear with us during this interim period.  Please be patient.  We will continue to fulfill requests and return calls as quickly as possible.

 

 

Employment Opportunity

COMPA’s Board of Directors has decided to move ahead with a replacement for Marty and is currently soliciting expressions of interest from those who wish to be considered for this position.  Those interested should submit an expression on interest, along with salary history and requirements, and a resume to Herb Barish at the Lower Eastside Service Center; 157 Chambers Street – 8th Floor; New York, NY 10007.  Applications must be received no later than May 15th and interviews will be held in New York and Albany during the last two weeks of May.  Please note that interested candidates must be willing and able to spend time in both New York City and Albany. 

 

COMPA Newsletter

COMPA will soon begin publishing a new Quarterly Newsletter which will be distributed to all organizational and individual members of COMPA.  Each edition of the newsletter will focus on a specific topic of interest to the field and will also include items such as quarterly meeting calendars and notices; conference announcements; training opportunities; committee reports;   resource listings; and letters from the Executive Director and the Board.  Articles are currently being solicited regarding Office Based Treatment and should be directed to Bob Krauss at the Long Beach Hospital MTP, 455 East Bay Drive, Long Beach, NY 11561. The first edition is expected before the Summer.

 

 

 

 

The COMPA Bulletin is written and distributed by:

The Committee of Methadone Program Administrators of NYS Inc.

250 Fifth Avenue, Suite 210

New York, N.Y. 10001

212-447-6682

www.compa-ny.org